Respiratory Syncytial Virus Vaccines Market Report: Market Size & Forecast 2026

The RSV vaccines market encompasses products designed to prevent lower respiratory tract disease caused by respiratory syncytial virus, a leading cause of hospitalization in infants and a growing concern in adults aged 60 and older. Following regulatory approvals in 2023, the market has rapidly scaled, with global revenues reaching roughly $2.5 billion in 2025. The market's expansion is anchored in high-burden populations, including older adults and pregnant women, and benefits from established reimbursement pathways in North America and Europe.

• •Estimated 2025 market value of approximately $2.5 billion worldwide.
• •Compounded annual growth rate of about 12.5% reflects post-approval uptake.
• •Approved products target older adults and maternal immunization to protect infants.

Sustained market expansion is primarily driven by the high disease burden of RSV in vulnerable populations and the recent introduction of effective recombinant subunit vaccines. Increasing healthcare provider awareness, broadening recommendations from public health agencies, and favorable cost-effectiveness data in older adults are accelerating adoption. Additional momentum comes from expanded maternal immunization programs and continued investment in pipeline candidates using mRNA and protein-based platforms.

• •Aging populations in North America, Europe, and parts of Asia are raising the addressable adult market.
• •Inclusion in national immunization schedules and reimbursement coverage is driving volume growth.
• •Pipeline diversification across mRNA, recombinant protein, and live attenuated platforms is sustaining long-term interest.

By indication, the market is segmented into older adult vaccination and maternal immunization for infant protection, with the older adult segment currently accounting for the larger share of revenue. North America leads on revenue, supported by early adoption, established reimbursement, and high public awareness, while Europe represents the second major region. The Asia-Pacific market is expected to record the fastest growth as approvals broaden and healthcare access improves in countries such as Japan, China, and Australia.

• •Older adult vaccines dominate current sales, with maternal products scaling rapidly.
• •North America holds the leading revenue position, followed by Europe.
• •Asia-Pacific is projected to be the fastest-growing regional segment over the forecast horizon.

What are the recent trends and outlook?

Near-term trends include expansion of vaccination programs into additional age groups and risk categories, alongside growing real-world evidence supporting vaccine effectiveness. Pipeline innovation is focused on mRNA platforms, combination respiratory vaccines, and improved durability of protection, which could further widen the addressable population. Looking ahead, the market is expected to sustain double-digit growth as access improves in emerging economies and as new entrants diversify available options.

• •Real-world effectiveness data is reinforcing clinician confidence and uptake.
• •Combination and next-generation mRNA candidates are a central area of pipeline investment.
• •Emerging markets represent the largest untapped opportunity for long-term expansion.